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ORIGINAL RESEARCH
Correlations of Calf Muscle Macrophage 
Content With Muscle Properties and 
Walking Performance in Peripheral Artery 
Disease
Kate Kosmac, PhD; Marta Gonzalez-Freire, PhD; Mary M. McDermott, MD; Sarah H. White, PhD;  
R. Grace Walton, PhD; Robert L. Sufit, MD; Lu Tian, ScD; Lingyu Li, MS; Melina R. Kibbe, MD;  
Michael H. Criqui, MD, MPH; Jack M. Guralnik, MD, PhD, MPH; Tamar S. Polonsky, MD, MSCI;  
Christiaan Leeuwenburgh, PhD; Luigi Ferrucci, MD, PhD; Charlotte A. Peterson, PhD
BACKGROUND: Peripheral artery disease (PAD) is a manifestation of atherosclerosis characterized by reduced blood flow to the 
lower extremities and mobility loss. Preliminary evidence suggests PAD damages skeletal muscle, resulting in muscle impair-
ments that contribute to functional decline. We sought to determine whether PAD is associated with an altered macrophage 
profile in gastrocnemius muscles and whether muscle macrophage populations are associated with impaired muscle pheno-
type and walking performance in patients with PAD.
METHODS AND RESULTS: Macrophages, satellite cells, and extracellular matrix in gastrocnemius muscles from 25 patients with 
PAD and 7 patients without PAD were quantified using immunohistochemistry. Among patients with PAD, both the absolute 
number and percentage of cluster of differentiation (CD) 11b+CD206+ M2- like macrophages positively correlated to satellite 
cell number (r=0.461 [P=0.023] and r=0.416 [P=0.042], respectively) but not capillary density or extracellular matrix. The num-
ber of CD11b+CD206− macrophages negatively correlated to 4- meter walk tests at normal (r=−0.447, P=0.036) and fast pace 
(r=−0.510, P=0.014). Extracellular matrix occupied more muscle area in PAD compared with non- PAD (8.72±2.19% versus 
5.30±1.03%, P<0.001) and positively correlated with capillary density (r=0.656, P<0.001).
CONCLUSIONS: Among people with PAD, higher CD206+ M2- like macrophage abundance was associated with greater satel-
lite cell numbers and muscle fiber size. Lower CD206− macrophage abundance was associated with better walking per-
formance. Further study is needed to determine whether CD206+ macrophages are associated with ongoing reparative 
processes enabling skeletal muscle adaptation to damage with PAD.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifiers: NCT00693940, NCT01408901, NCT0224660.
Key Words: macrophage ■ peripheral artery disease ■ skeletal muscle ■ walking performance
Peripheral artery disease (PAD) is characterized by lower extremity muscle discomfort, weakness and pain during walking and is frequently accompa-
nied by a reduction in physical activity, walking speed, 
endurance, and quality of life.1–6 Artery narrowing may 
occur over months or years and the consequent re-
duction of blood flow to the lower limbs results in is-
chemia during walking followed by reperfusion during 
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rest, both contributing to muscle damage.7,8 Muscle 
ischemia- reperfusion injury in PAD is associated with 
mitochondrial disruption, production of free radicals, 
and inflammation.7,9,10 Although revascularization is 
effective at restoring blood flow, vascular stenting is 
invasive, is not appropriate for many patients with PAD, 
and does not have long- term durability.11 Supervised 
exercise is an effective therapy for improving walking 
performance in PAD but does not alter lower extremity 
blood flow, suggesting that stimulating adaptive mus-
cle responses in addition to restoring blood flow may 
provide an effective strategy to reverse muscle dys-
function with PAD.12–15
Skeletal muscle injury and repair are associated with 
macrophage infiltration, studied primarily in the context of 
acute injury via toxin injection into muscle in rodents.16–21 
Macrophages have also been shown to infiltrate human 
muscle following acute injury induced by electrical stim-
ulation.22 Macrophages are highly adaptive immune cells 
with a continuum of phenotypes and polarization states. 
Although conventional classification is oversimplified 
and inadequate, particularly with regard to tissue resi-
dent macrophages, they are commonly referred to as 
classically activated, inflammatory M1 or alternatively ac-
tivated, anti- inflammatory M2 within the context of mus-
cle regeneration.21,23 Muscle repair is a tightly regulated 
process with initial infiltration of neutrophils that exacer-
bate damage, followed by M1 macrophages that phago-
cytize debris and secrete inflammatory cytokines. M1 
macrophages are then replaced by M2 macrophages 
that secrete anti- inflammatory cytokines and factors that 
promote extracellular matrix (ECM) accumulation during 
wound healing.24–28 Furthermore, M2 macrophages pro-
duce growth factors that promote stem cell recruitment29 
and function following skeletal muscle injury.30–32 Muscle 
stem cells, satellite cells, are directly responsible for mus-
cle regeneration following injury33,34 and in vitro studies 
have shown that macrophages directly affect satellite 
cell proliferation and differentiation.24,35 The role of sat-
ellite cell- dependent muscle repair and the interplay with 
macrophage populations in response to chronic muscle 
damage associated with PAD is unknown.
Inflammation is associated with PAD sever-
ity and progression.36–38 Systemically, increases 
in mRNA levels of inflammatory biomarkers occur 
within peripheral blood monocytes36 and it is well 
established that people with PAD have elevated cir-
culating concentrations of inflammatory markers 
such as C- reactive protein and interleukin 6 com-
pared with people without PAD.38–44 Among people 
with PAD, higher circulating inflammatory markers 
are associated with greater calf (gastrocnemius) 
skeletal muscle damage45 and have been linked to 
poorer functional outcomes.46,47 However, reports 
on the relative abundance of different macrophage 
populations in response to ischemia in muscle are 
inconsistent. Recent work showed a greater abun-
dance of macrophages, particularly M1- like cluster 
of differentiation (CD) 80+ macrophages, in muscles 
of PAD patients with intermittent claudication com-
pared with people without PAD.48 On the other hand, 
CLINICAL PERSPECTIVE
What Is New?
• People with peripheral artery disease (PAD) 
had higher cluster of differentiation (CD) 206+ 
macrophage abundance and extracellular ma-
trix within the gastrocnemius muscle compared 
with those without PAD.
• In patients with PAD, CD206+ macrophage abun-
dance was associated with gastrocnemius mus-
cle stem cell content and fiber size, consistent 
with the hypothesis that CD206+ macrophages 
coordinate muscle maintenance and repair dur-
ing chronic ischemia-reperfusion injury with PAD.
• In the gastrocnemius muscle of patients with 
PAD, higher extracellular matrix was associated 
with higher capillary density; higher numbers 
of CD206− macrophages negatively correlated 
with 4-meter walking performance in patients 
with PAD.
What Are the Clinical Implications?
• CD206+ macrophage-mediated reparative pro-
cesses may be ongoing in gastrocnemius mus-
cles of people with PAD and targeting these 
processes could preserve walking performance.
• Restoring blood flow in conjunction with pro-
moting adaptive muscle responses may provide 
the most effective approach to improve walking 
performance in patients with PAD.
Nonstandard Abbreviations and Acronyms
ABI ankle-brachial index
BRAVO  Biomarker Risk Assessment in Vulnerable 
Outpatients
CD cluster of differentiation
ECM extracellular matrix
FCGR3B  Fc fragment of IgG, low affinity IIIb, receptor
GOALS Group Oriented Arterial Leg Study
PAD peripheral artery disease
PROPEL  Progenitor Cell Release Plus Exercise 
Improve Functional Performance in PAD
RESTORE  Resveratrol to Improve Outcomes in 
Older People With PAD
SR Sirius Red
WALCS III  Walking and Leg Circulation Study III
WGA wheat germ agglutinin
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M2- like macrophages promote angiogenesis and are 
higher in ischemic muscle than in normoxic muscle 
from the same patient with critical limb ischemia.49 
Studies in rodent models of hind limb ischemia have 
demonstrated the association of macrophage pop-
ulations with muscle damage, inflammation and 
recovery following experimental blood flow restric-
tion.48–54 Altering gene expression to disrupt macro-
phage M2 differentiation following arterial resection/
ligation in mouse hind limb muscles resulted in in-
creased M1 macrophages and decreased angiogen-
esis.50 Similarly, a greater abundance of inflammatory 
M1 macrophages was associated with impaired 
walking early following artery ligation in mice.51 Liu 
et al52 reported that treatment of mice with the anti- 
inflammatory/antioxidant, curcumin, following hind 
limb ischemia decreased macrophage infiltration 
and was associated with improved treadmill running. 
Other studies have suggested that M2 macrophages 
are beneficial, promoting angiogenesis in muscle fol-
lowing ischemia- induced limb injury in rodents.49,55–58
We recently characterized macrophages resident 
in healthy human skeletal muscle, independent of in-
jury, using both fluorescence- activated cell sorting 
and immunohistochemistry.59 These analyses showed 
that CD11b is present on all resident muscle macro-
phages and only a very small subpopulation lack the 
well- accepted M2 cell surface marker CD206. In a 
separate study, the abundance of CD206- expressing 
macrophages increased with exercise training, and 
a higher abundance of CD206+ macrophages was 
associated with increased muscle fiber size and sat-
ellite cell abundance, suggesting that CD206+ mac-
rophages in humans promote muscle adaptation and 
are, therefore, M2- like.60 The purpose of this study 
was to quantify macrophage content in gastrocne-
mius muscles from individuals with PAD, compared 
with those without PAD, and to relate macrophage 
abundance and subtypes with walking performance 
in people with PAD. First, we hypothesized that those 
with PAD would have a higher abundance of macro-
phages lacking M2 cell surface markers (CD206 and 
CD163) than those without PAD, reflecting a more 
inflammatory M1- like phenotype,48 which would be 
related to disease severity. Second, we hypothesized 
that among people with PAD, a higher relative abun-
dance of CD206+ M2- like macrophages would be 
associated with greater capillary density and satellite 
cell content and better walking performance.
MATERIALS AND METHODS
The data that support the findings of this study 
are available from the corresponding author upon 
request.
Participants
Five observational studies or clinical trials at 
Northwestern University Feinberg School of 
Medicine were accessed to identify patients with 
PAD and those without PAD. ClinicalTrials.gov iden-
tifiers are listed where applicable. The studies ac-
cessed included 2 observational studies (WALCS 
III [Walking and Leg Circulation Study III]61–63 and 
BRAVO [Biomarker Risk Assessment in Vulnerable 
Outpatients], NCT0227678161,64,65) and 3 randomized 
trials (GOALS [Group Oriented Arterial Leg Study], 
NCT00693940; PROPEL [Progenitor Cell Release 
Plus Exercise Improve Functional Performance in 
PAD], NCT0140890166–68; and RESTORE [Resveratrol 
to Improve Outcomes in Older People With PAD], 
NCT0224660). Data for participants randomized 
into clinical trials were collected at baseline, and 
participants did not receive any study interventions 
before muscle biopsies. All studies were performed 
in accordance with the Declaration of Helsinki and 
were approved by the institutional review board at 
Northwestern University. All participants provided 
written informed consent before enrollment in any 
study. All procedures were performed at baseline, 
before interventions. Medications were identified by 
asking participants to bring their medication bot-
tles to the baseline study visit or compose a list of 
their current medications. A trained professional re-
viewed each medication (M.M.M.) and we previously 
reported the number of patients taking statins.69 
Intermittent claudication was determined using the 
San Diego claudication questionnaire and according 
to published methods.70 Detailed comorbidities and 
medications of this cohort of PAD (n=25) and non- 
PAD (n=7) are presented in Table 1.
Inclusion and Exclusion Criteria
Participants with a baseline ankle- brachial index 
(ABI) of <0.90 were classified as having PAD, while 
participants with baseline ABI values between 0.9 
and 1.30 were considered non- PAD. The inability 
to walk without aide (walker or wheelchair), occur-
rence of a recent major health incident (operation or 
cardiovascular event), presence of significantly im-
paired cognitive function, and/or terminal illness war-
ranted exclusion according to reported criteria.61,64–68 
Questionnaires, administered in a standard fashion, 
were used to determine the presence of comorbidi-
ties, such as diabetes mellitus and smoking history. 
One patient with PAD included in our prior publica-
tion (n=26)69 did not have a sufficient muscle biopsy 
sample for these analyses and was not included in 
the findings reported here. Walking performance 
data were only collected for participants with PAD, 
and only those individuals in which the data were 
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obtained within 6 months of the muscle biopsy were 
included in functional analyses (n=23 of the 25 par-
ticipants with PAD).
Ankle- Brachial Index
The ABI was measured as previously described.69 
A handheld Doppler probe (Nicolet Vascular Pocket 
Dop II) was used to obtain systolic blood pressures 
at the following locations: right brachial, dorsalis 
pedis, and posterior tibial arteries; and left dorsalis 
pedis, posterior tibial, and brachial arteries following 
5 minutes of rest in the supine position. Dividing the 
average of the dorsalis pedis and posterior tibial pres-
sures in each leg by the average of the brachial pres-
sures gives the calculated ABI for each leg.71,72 Only 
the ABI measurement from the leg with the lower ABI 
was used in determining associations with muscle 
features; this was also the leg used to obtain muscle 
biopsies. Using only either the highest or lowest of 
the 2 leg pressures did not change the reported out-
comes (data not shown).
Six- Minute Walk
Using a standardized script, a certified research co-
ordinator asked patients to complete as many laps as 
possible in 6 minutes, walking back and forth in a 100- 
foot hallway.2,5,73,74 Participants were asked to walk 
continuously, but, if rest was needed, participants were 
allowed to stop during the 6 minutes. Standardized en-
couragement was given to help participants complete 
the task and be aware of their progress. A research 
assistant walked with and slightly behind the partici-
pant, so that the research assistant did not pace the 
participant.
Four- Meter Walk Tests
Patients were asked to walk a 4- meter distance at 
both “normal” and “fast” speeds. For each speed, the 
task was performed twice and time to complete the 
4- meter distance was recorded.75,76 The faster walk for 
each speed was used to calculate walking velocity.
Muscle Biopsies
Muscle biopsies were obtained at baseline, before 
any trial intervention, from the medial head of the gas-
trocnemius muscle as described in detail elsewhere.69 
Approximately 100 mg of tissue was embedded in tra-
gacanth gum on cork, frozen in liquid- nitrogen cooled 
isopentane, and stored at −80°C. Biopsies were sec-
tioned in a cryostat with a chamber temperature of 
−22 to −25°C at a thickness of 7 μm. Before immuno-
histochemical or histochemical analyses, slides were 
removed from storage at −20°C and air dried at room 
temperature for 10 to 15 minutes.
Immunohistochemistry
Macrophage identification and quantification were 
performed according to a detailed and validated 
method.59 Briefly, macrophages were identified by 
stepwise staining with antibodies against the pan 
macrophage marker CD11b (Cell Sciences) or the 
M2c macrophage marker CD163 (Hycult Biotech), 
followed by CD206, a marker of M2 macrophages 
(R&D Systems) (Table S1). For staining, slides were 
fixed in −20°C acetone and blocking steps were 
taken to prevent nonspecific background staining 
and cross- reactivity between amplification reagents. 
CD11b, CD163, and CD206 labeling was amplified 
using a biotin, streptavidin system. For CD11b or 
CD163, an extra amplification step with fluorophore- 
conjugated tyramide signal amplification reagent was 
performed. Sections were washed and nuclei were 
visualized using 4′,6- diamidino- 2- phenylindole (DAPI) 
Table 1. Characteristics of Participants Without and 
Participants With PAD
Non- PAD (N=7)† PAD (N=25) P Value
Age, y 72.1±6.1 68.1±10.1 0.205
ABI 1.13±0.11 0.62±0.13 <0.001*
BMI† 25.1±2.5 28.2±4.9 0.156
Men, % 57.1 60.0 1.000
Black race, % 28.6 76.0 0.032*
Diabetes mellitus, 
%†
0.0 36.0 0.530
Hypertension, %† 33.3 88.0 0.073
Heart failure, %† 0.0 0.0 NA
Pulmonary 
disease, %†
0.0 20.0 1.000
Angina, %† 0.0 8.0 1.000
Myocardial 
infarction, %†
0.0 8.0 1.000
Cancer, %† 66.7 12.0 0.073
Current smoker, %† 0.0 52.0 0.226
Intermittent 
claudication, %†
0.0 24.0 1.000
Walking exercise 
frequency past wk†
1.33±1.53 1.28±2.70 0.962
Medications, No. (%)
ACEIs or ARBs 4 (57.1) 14 (56.0) 1.000
Antiplatelets 1 (14.3) 18 (72.0) 0.010*
Statins 4 (57.1) 20 (80.0) 0.327
Cilostazol or 
pentoxifylline
0 (0.00) 5 (20.0) 0.560
Values are expressed as mean±SD. ABI indicates ankle- brachial index; 
ACEIs, angiotensin- converting enzyme inhibitors; ARBs, angiotensin receptor 
blockers; BMI, body mass index; and PAD, peripheral artery disease.
*Statistically significant P<0.05.
†Based on n=3 non-PAD participants.
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(ThermoFisher). After staining, slides were cover-
slipped with Vectashield (Vector Laboratories, H- 1000) 
and stitched images of whole muscle cross- sections 
were acquired with a 20× objective. The abundance 
of all CD11b- expressing cells (total macrophages), 
CD11b+CD206−, and CD11b+CD206+ were manually 
quantified using the event count tool in Zen software 
(Zeiss). For samples with remaining tissue (n=6 non- 
PAD, n=18 PAD), CD163+CD206+ macrophages were 
also quantified. Of note, CD163 and CD11b staining 
cannot be performed on the same samples because 
of amplification cross- reactivity; however, the propor-
tion of CD206+ macrophages co- expressing CD163 
was between 89% and 99.7%, supporting the idea 
that CD206+ macrophages are M2- like.
A primary antibody against CD16B/FCGR3B 
(LifeSpan BioSciences, Inc), a neutrophil- specific 
marker in human tissue, was used to assess the pres-
ence of neutrophils within muscle samples. For stain-
ing, sections were fixed for 30  minutes with Bouin 
fixative (Electron Microscopy Sciences, 15990), dehy-
drated with xylenes, and rehydrated with decreasing 
concentrations of ethanol. Heat- induced epitope re-
trieval was performed by incubating slides in sodium 
citrate buffer within a heated water bath, beginning at 
65°C and heating to 92°C, then incubating at 92°C for 
an additional 20 minutes. Slides were cooled to room 
temperature and washed with distilled water. Nuclei 
were counterstained with hematoxylin, washed in tap 
water, differentiated with acidified ethanol, blued in 
Scott water, and rinsed before blocking. Endogenous 
alkaline phosphatases were quenched by incu-
bating sections for 10  minutes with Bloxall reagent 
(Vector Laboratories, SP- 6000). Sections were then 
washed, blocked for 1 hour with 2.5% normal horse 
serum (Vector Laboratories, S- 2012) and incubated 
with primary antibody for 2  hours at room tempera-
ture. CD16 antibody was amplified using ImmPRESS 
AP (alkaline phosphatase) anti- rabbit polymer (Vector 
Laboratories, MP- 5401) and visualized by incubation 
with the alkaline phosphatase substrate, Vector Red 
(Vector Laboratories, MP- 7401), according to the man-
ufacturer’s instructions. After staining, slides were 
coverslipped with VectaMount AQ Aqueous Mounting 
Medium (Vector Laboratories, H- 5501) and represen-
tative images were acquired using transmitted light 
microscopy.
ECM was quantified using α- wheat germ agglu-
tinin (WGA), which binds to glycosaminoglycans.77 
After fixation with 4% paraformaldehyde, sections 
were washed with PBS then incubated with Texas 
Red–conjugated WGA for 2  hours (ThermoFisher). 
Sections were washed and coverslipped with 
Vectashield. Stitched images of whole muscle 
cross- sections were acquired with a 10× objective. 
Quantification of WGA was performed by setting a 
threshold for positive staining and determining the 
percent of total area in the region of interest occu-
pied by this threshold. At least 3 regions of interest/
section were analyzed using the interactive mea-
surement wizard in AxioVision software version 4.2.8 
(Zeiss). Total collagen content within the ECM was 
quantified with Sirius Red (SR) staining. Collagens 
within muscle sections were denatured by fixing for 
15  minutes with Bouin fixative at 56°C in a sealed 
chamber within a heated water bath. Following fixa-
tion, the sealed chamber was transferred to a chem-
ical fume hood, Bouin fixative was removed, and 
slides were washed with distilled water. Following the 
final wash, slides were incubated for 2 hours in 0.1% 
SR staining solution (Electron Microscopy Sciences, 
26357- 02). Following staining, slides were washed in 
0.5% acetic acid in distilled water, dehydrated in 95% 
ethanol followed by 100% ethanol, and equilibrated 
in xylenes. Slides were mounted with Cytoseal 60 
(ThermoFisher, 8311), which was allowed to harden 
in a chemical fume hood for 24 hours. Whole muscle 
cross- sections were imaged with a 10× objective and 
quantification of SR was performed similar to WGA 
quantification.
To visualize collagen surrounding capillaries, frozen 
muscle sections were dried and rehydrated for 5 min-
utes with 1x PBS, followed by two 5- minute washes 
with PBS. Sections were blocked for 1 hour in 2.5% 
normal horse serum then incubated for 90  minutes 
with a mixture of 2 lectins: biotinylated Ulex euro-
paeus (Vector Laboratories) and biotinylated Griffonia 
Simplicifolia (Vector Laboratories), and a pan- collagen 
antibody (ThermoFisher). Sections were then washed 
and incubated for 1 hour with Streptavidin Alexa Fluor 
594 (ThermoFisher) to visualize capillaries and anti- 
Rabbit Alexa Fluor 488 (ThermoFisher) to visualize 
collagen. After 3 final washes, the slides were covers-
lipped with Vectashield and imaged.
Analysis of satellite cell abundance was performed 
as follows. After drying at room temperature, sections 
were fixed in −20°C acetone, washed with PBS, in-
cubated with 3% hydrogen peroxide, and blocked for 
1 hour in 2.5% normal horse serum. Satellite cells were 
labelled by overnight incubation with anti–paired box 
7 (Pax7) (Developmental Studies Hybridoma Bank, 
University of Iowa). Following PBS washes, sections 
were incubated with biotinylated anti- mouse IgG1 
(Jackson ImmunoResearch Laboratories) for 90 min-
utes. Washes were repeated followed by a 1- hour 
incubation with streptavidin horseradish peroxidase 
(ThermoFisher). Fluorescent labelling was achieved 
by incubating with SuperBoost tyramide signal am-
plification Alexa Fluor 488 in PBS (ThermoFisher) 
for 20  minutes. Primary antibody against laminin 
(Millipore Sigma) was added followed by anti- Rabbit 
Alexa Fluor 594 secondary antibody (ThermoFisher) 
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to visualize and quantify muscle fibers. Sections 
were washed, incubated for 10 minutes with DAPI to 
label nuclei, and coverslipped. Whole cross- section 
images were acquired with a 20× objective, satellite 
cells were identified as Pax7+/DAPI+, and quantifi-
cation was expressed relative to laminin- delineated 
fiber number. Laminin- stained images were previ-
ously used to determine fiber size by minimum feret 
diameter.69
For a detailed list of all antibodies used for immu-
nohistochemistry, see Table S1. An Axio Imager M1 
(Zeiss) equipped with both ZEN software (blue edi-
tion, v2.3) and AxioVision (4.8.2) was used to capture 
stitched images of whole muscle cross- sections for all 
image quantification.
Statistical Analysis
Continuous variables were summarized with mean 
and SD, except the abundance of macrophage pop-
ulations between non- PAD and PAD, which shows 
mean and standard error (SE). Categorical vari-
ables were compared using Fisher exact test. The 
distribution of continuous variables was assessed 
graphically and there were no statistically significant 
violations of normal distribution assumption for any 
of the variables of interest. Since the proportion of 
black patients was statistically significantly differ-
ent between non- PAD and PAD, we compared the 
muscle measures between participants with PAD 
and those without PAD (shown in Table 2) based on 
t tests (without assuming equal variance) stratified by 
race. Specifically, we compared PAD with non- PAD 
in black and white participants, separately, and then 
combined the test results using Mantel–Haenszel 
weights. Partial correlation coefficients (r) were esti-
mated to quantify relationships among muscle char-
acteristics and walking performance within PAD after 
adjustment of race. The 95% CIs for partial corre-
lation coefficients were determined using Fisher Z 
transformation. Statistical analyses were performed 
using SAS version 9.4 (SAS Institute Inc) and graphs 
were made using Prism 7 (GraphPad Software). All 
tests were 2- tailed (α<0.05).
Table 2. Race- Adjusted Muscle Characteristics in 
Participants With and Without PAD 
Non- PAD (N=7)* PAD (N=25)† P Value
Total macrophages, 
per fiber*
0.44±0.16 0.63±0.36 0.139
CD11b+CD206−, per 
fiber*
0.14±0.05 0.16±0.09 0.685
CD11b+CD206+, per 
fiber*
0.30±0.11 0.48±0.29 0.094
CD11b+CD206+, % of 
total macrophages*
67.69±2.97 74.03±8.74 0.036‡
Satellite cells, per 100 
fibers
29.14±14.25 28.06±14.75 0.930
ECM, % of total area† 5.30±1.03 8.72±2.19 <0.001‡
SR staining, % of total 
area†
5.07±1.19 7.74±2.88 0.041‡
Values are expressed as mean±SD. CD indicates cluster of differentiation; 
ECM, extracellular matrix; PAD, peripheral artery disease; and SR, Sirius 
Red.
*Based on n=6 non-PAD participants.
†Based on n=24 patients with PAD.
P value is adjusted for race, ‡statistically significant P<0.05.
Figure  1. Representative images of total cluster of 
differentiation (CD) 11b+, CD206−, and CD206+ macrophage 
abundance in the gastrocnemius muscle of patients with 
peripheral artery disease (PAD) compared with patients 
without PAD.
A, Total muscle macrophages in patients without PAD (left) and 
patients with PAD (right) visualized by immunohistochemistry 
with an antibody against the pan- macrophage marker CD11b 
(green). Scale bar=200  µm. B, Higher magnification images of 
macrophages from boxed regions in panel A, showing CD11b+ 
(green) macrophages, CD206+ (red) macrophages, and the 
merged images, also overlaid with DAPI staining of nuclei (blue). 
Whereas the majority of macrophages are CD11b+CD206+, 
white arrows indicate CD11b+CD206− macrophages. Scale 
bar=200 µm. 
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RESULTS
Participant Characteristics
The demographic and clinical characteristics of the 
study population are shown in Table 1. Gastrocnemius 
muscle biopsies were analyzed from 25 participants 
with PAD and 7 participants without PAD. Muscle fiber 
size and fiber type distribution, mitochondrial mark-
ers, autophagy markers, and capillary density in mus-
cle biopsies from these individuals were previously 
reported.69
Higher Ratio of CD206+ to CD206− 
Macrophages in Gastrocnemius Muscles 
From Patients With PAD Compared With 
Patients Without PAD
Macrophages were quantified on gastrocnemius mus-
cle cross- sections using immunohistochemistry with 
antibodies against the cell surface markers CD11b, a 
pan macrophage marker in muscle, and CD206, an 
accepted M2 macrophage marker, both previously 
validated in human muscle.59 Representative images 
in Figure  1 (Figure  1A and the higher magnification 
of the boxed region in Figure 1B) show total CD11b+ 
macrophages and coexpression of CD206 on the ma-
jority of CD11b+ macrophages. Quantification of the 
total number of CD11b+ macrophages showed that 
the average number of macrophages/fiber was higher 
in muscles from participants with PAD compared with 
participants without PAD, but the difference did not 
reach statistical significance after adjusting for race 
(0.63/fiber versus 0.44/fiber, P=0.139) (Figure  2A), 
likely attributable to the highly variable number of 
total macrophages in muscles from participants with 
PAD compared with patients without PAD (0.07–1.57/
fiber versus 0.23–0.66/fiber, respectively). There was 
no difference in CD11b+CD206− macrophages/fiber 
(Figure 1B, arrows) between PAD and non- PAD mus-
cles (race- adjusted) (Figure 2B). Immunohistochemical 
analysis of neutrophils using an antibody against 
the neutrophil specific marker CD16B showed few 
CD16B+ cells in muscle from either non- PAD or PAD 
(data not shown). In PAD muscles, there was a trend 
for higher CD11b+CD206+ macrophages/fiber com-
pared with non- PAD muscles (P=0.094) (Figure  2C). 
As a result, the relative abundance of CD206+ mac-
rophages, expressed as a percentage of total CD11b+ 
Figure 2. Quantification of macrophage content in gastrocnemius muscle cross- sections. 
A through D, Non-peripheral artery disease (non- PAD, n=6), peripheral artery disease (PAD) (n=25).
Data are expressed as mean±SE; P values adjusted for race, *significance P≤0.05. A, Total cluster 
of differentiation (CD) 11b+ macrophages in patients with PAD compared with patients without PAD. 
B, CD11b+CD206− macrophages in patients without PAD and patients with PAD. C, CD11b+CD206+ 
macrophages in patients without PAD and patients with PAD. D, Relative abundance (% of total) of CD206− 
and CD206+ macrophages in patients with PAD and patients without PAD. E, Association of the M2c 
macrophage marker CD163 with the number of CD206+ macrophages, supporting CD206+ macrophages 
as M2- like. Non- PAD (n=5), PAD (n=18). Association determined by Pearson product moment correlation, 
r=partial correlation coefficient.
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macrophages (% of total [race- adjusted]) (Figure 2D), 
was significantly greater in PAD compared with non- 
PAD muscles (P=0.036) (Figure 2D).
All values are displayed in Table 2 and collectively 
show that CD206+ macrophages are the predominant 
macrophage population in skeletal muscles from all 
participants. These are likely M2- like macrophages, as 
the majority of CD206+ macrophages (89.3–99.7%) 
also expressed CD163, another M2 cell surface marker, 
and the number of CD163+ macrophages significantly 
correlated to the number of CD11b+CD206+ mac-
rophages on adjacent sections (r=0.782, P<0.0001) 
(Figure  2E). Macrophage content was not correlated 
to ABI (Table S2), a widely accepted measure of PAD 
severity.3,5,78
CD206+ Macrophages are Positively 
Associated With Satellite Cell Number and 
Fiber Size But Not Capillary Density in 
PAD Gastrocnemius Muscle
Immunohistochemistry for satellite cell content 
(Figure  3A through 3C), expressed as the number 
of Pax7+ nuclei/100 fibers, showed no difference in 
gastrocnemius muscle cross- sections between PAD 
and non- PAD (Table  2, all values race- adjusted). 
Scatter plots shown in Figure 4 illustrate positive cor-
relations between the relative abundance of CD206+ 
macrophages and satellite cell content (r=0.416, 
P=0.042) (Figure 4A), as well as CD206+ macrophages 
and mean fiber size (r=0.397, P=0.054) (Figure  4B) 
within PAD muscles. In PAD muscles, satellite cell 
content also positively correlated with mean fiber 
size (r=0.557, P=0.004) (Figure 4C). In addition to the 
relative abundance, the absolute number of CD206+ 
macrophages/fiber positively correlated to satellite cell 
content (r=0.461, P=0.023) (Table S2). Double immu-
nohistochemistry with CD206 and Pax7 antibodies 
showed that CD206+ macrophages were frequently 
Figure 3. Representative images of muscle satellite cells 
with laminin- demarcated muscle fibers in gastrocnemius 
from peripheral artery disease (PAD).
A, Paired box 7+ (Pax7+) (green) staining overlapping cell nuclei 
(DAPI, blue) identifies satellite cells. Scale bar=200 µm. B, Laminin 
demarcating muscle fiber borders (red). Scale bar=200 µm. C, 
Higher magnification showing satellite cells located beneath 
the laminin- stained basal lamina. White arrows point to satellite 
cell nuclei; Pax7 (green), nuclei (DAPI, blue), laminin (red). Scale 
bar=100 µm.
Figure 4. Relative abundance of cluster of differentiation 
(CD) 206+ macrophages is positively associated with 
satellite cell number and fiber size in the gastrocnemius 
muscle from patients with peripheral artery disease 
(PAD).
Scatterplots showing correlations between the relative 
abundance of CD206+ macrophages and (A) satellite cell 
content and (B) fiber size, measured by minimum feret 
diameter. C, Correlation between satellite cells and fiber size. 
For all measures, relationships determined by Pearson product 
moment correlation adjusting for race, r=partial correlation 
coefficient, PAD (n=25). D, Representative images showing 
a satellite cell (paired box 7 [Pax7]+, green) and a CD206+ 
macrophage (red) in close proximity. DAPI (blue) stains nuclei. 
Scale bar=20 µm. 
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 15, 2020
J Am Heart Assoc. 2020;9:e015929. DOI: 10.1161/JAHA.118.015929 9
Kosmac et al Muscle Macrophage Abundance and Function in PAD
found in close proximity to satellite cells (Figure 4D and 
Figure S1).
We previously measured capillary density within 
gastrocnemius muscle from these volunteers and re-
ported higher capillary density within muscles from pa-
tients with PAD compared with those without PAD.69 
Here we report that among people with PAD, capillary 
density was not correlated to CD206+ macrophage 
number or relative abundance (r=0.027 [P=0.905] and 
r=0.179 [P=0.417], respectively) (Table S2).
ECM and Collagen Content are Higher in 
PAD Gastrocnemius Muscle Compared 
With Non- PAD and Correlate to Capillary 
Density
ECM surrounding muscle fibers, measured by fluores-
cent WGA staining (representative images, Figure 5A), 
was greater in gastrocnemius muscles from patients 
with PAD compared with those without PAD (P<0.001) 
(Figure 5B and Table 2; all values race- adjusted). In PAD 
muscle, WGA staining was positively correlated to cap-
illary density (r=0.656, P<0.001) (Figure 5C). To further 
characterize ECM abundance, we analyzed total fibrous 
collagen content using Sirius Red (SR) (Figure  6A). 
Similar to WGA, collagen (SR+ area) surrounding mus-
cle fibers was greater in PAD muscle compared with 
non- PAD (P=0.041) (Figure 6B and Table 2), and the 2 
ECM measures were significantly correlated to each 
other (r=0.443, P=0.013) (Figure 6C). SR staining ap-
peared particularly prominent surrounding capillaries 
in PAD muscle (Figure S2A). Immunohistochemistry 
with a pan- collagen antibody combined with lectins to 
specifically stain capillaries79 showed collagen depo-
sition surrounding capillaries (Figure S2B). In addition, 
some cross- sectional capillaries appeared filled with 
collagen in PAD muscle (Figure S2B, blue arrows). 
No associations were observed between CD206+ 
macrophages and ECM or collagen content (data not 
shown), and none of these muscle properties were 
correlated to ABI in patients with PAD (Table S2).
CD206− Macrophages are Negatively 
Associated With Walking Performance in 
PAD
The abundance of CD206− macrophages/fiber nega-
tively correlated to 4- meter walk tests both at normal 
(r=−0.447, P=0.036) (Figure 7A) and fast pace (r=−0.510, 
Figure  5. Peripheral artery disease (PAD) gastrocnemius 
muscles show higher extracellular matrix (ECM) content 
compared with non- PAD.
A, Representative images of gastrocnemius muscle showing 
fluorescently labeled α- wheat germ agglutinin (WGA) staining 
of glycosaminoglycans in the ECM between muscle fibers 
in patients without PAD and patients with PAD, quantified in 
(B). Scale bar=200  µm. Non- PAD (n=7), PAD (n=24). Data are 
expressed as mean±SD; P values adjusted for race, *significance 
P≤0.05. C, Correlation of ECM content with capillary density (the 
number of lectin+ capillaries/fiber) in patients with PAD (n=24), 
determined by Pearson product moment correlation adjusting for 
race, r=partial correlation coefficient. No relationship between 
ECM content and capillary density was observed in non- PAD 
samples (data not shown).
Figure  6. Peripheral artery disease (PAD) gastrocnemius 
muscles show higher collagen content compared with non- 
PAD.
A, Representative images of gastrocnemius muscle showing 
Sirius Red (SR) staining of collagens between muscle fibers 
in patients without PAD and patients with PAD, quantified in 
(B). Scale bar=200  μm. Non- PAD (n=7), PAD (n=24). Data are 
expressed as mean±SD; P values adjusted for race, *significance 
P≤0.05. C, Correlation of collagen content (SR+ area) with 
extracellular matrix (ECM) content (α- wheat germ agglutinin 
[WGA]+ area) in all patients (n=31), determined by Pearson 
product moment correlation, r=partial correlation coefficient.
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P=0.014) (Figure 7B) in participants with PAD. CD206+ 
macrophages did not correlate to 4- meter walking per-
formance and there were no statistically significant cor-
relations between any muscle measures and 6- minute 
walk distance (data not shown).
DISCUSSION
In this cross- sectional study of calf muscle biopsies, we 
observed higher average macrophages/fiber in people 
with PAD compared with those without PAD, which was 
attributable to a higher abundance of CD11b+CD206+ 
macrophages. The majority of CD206+ macrophages 
coexpressed CD163, supporting the idea that they are 
anti- inflammatory and M2- like. Among people with PAD, 
the greater relative abundance of CD206+ macrophages 
was associated with greater satellite cell content and 
larger mean fiber size, further supporting the idea that 
CD206+ macrophages are M2- like and may promote re-
parative processes in lower extremity muscles of people 
with PAD. In response to skeletal muscle damage, sat-
ellite cells proliferate, differentiate, and fuse into muscle 
fibers to repair and maintain fiber number and size.33,34 
M2 macrophages facilitate satellite cell function through 
the production of growth and differentiation factors, 
such as insulin- like growth factor 1.30–32 Adjusting for 
race attenuated a positive relationship between the rela-
tive abundance of CD206+ macrophages and 4- meter 
walking performance, suggesting that the association of 
CD206+ macrophage abundance with walking perfor-
mance among participants with PAD reported here may 
be confounded by race.80,81 Further study with a larger 
sample size is needed.
To our knowledge, this is the first study to report 
an association between satellite cells and CD206+, 
M2- like macrophage abundance in PAD, although 
several studies have shown satellite cell- macrophage 
interactions during acute muscle injury and regenera-
tion in rodent models.24,35,82,83 Recent work in the mdx 
mouse model of Duchenne muscular dystrophy has 
highlighted macrophage contributions to regenerative 
muscle responses in this degenerative disease.84–86 In 
particular, promoting M2 macrophage polarization in 
mdx mouse muscle increased proregenerative mus-
cle responses, resulting in increased muscle mass, 
fiber size, strength, and function.84 Direct communi-
cation between CD206+ macrophages and satellite 
cells in mdx mouse muscle may be mediated by the 
protein Klotho and contributes to muscle fiber size.86 
Additionally, macrophage depletion in mdx mice in-
creases collagen and fat deposition and converts satel-
lite cell pools to adipogenic, intensifying the dystrophic 
phenotype.85 Results reported here, in people with 
PAD, are consistent with the idea that M2- like macro-
phages may directly interact with satellite cells and may 
facilitate satellite cell–mediated maintenance of muscle 
fibers in the face of chronic ischemia- reperfusion injury 
occurring with PAD.
Animal models of hind limb ischemia have pri-
marily focused on acute ischemic injury, which is 
characterized by the induction of inflammatory M1 
macrophages.25,48,51–54 However, acute injury mod-
els are unlikely to represent the pathology, nor po-
tential skeletal muscle adaptations, associated with 
gradual onset and long- term exposure of lower ex-
tremity human skeletal muscle to repeated bouts of 
ischemia- reperfusion, characteristic of PAD.87–89 In 
fact, a study by Tang et al90 showed that acute arterial 
occlusion in rats resulted in inflammation, inflamma-
tory cell infiltration, and muscle necrosis, which was 
absent following gradual arterial occlusion. Thus, 
macrophage phenotypes in ischemic muscle may 
differ depending on the rate of blood flow restriction 
Figure 7. Cluster of differentiation (CD) 206− 
macrophages in gastrocnemius muscle are 
associated with poor walking performance in 
patients with peripheral artery disease (PAD).
Scatterplots showing correlations between 
the abundance of CD206− macrophages and 
functional performance measured with (A) 
4- meter normal pace test (95% CI of r=−0.726 
to −0.021), (B) 4- meter fast pace test (95% 
CI of r=−0.762 to −0.101) For all measures, 
relationships determined by Pearson product 
moment correlation adjusting for race, r=partial 
correlation coefficient, PAD (n=23).
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during PAD progression,90,91 which may explain the 
variability we observed in total macrophage abun-
dance across PAD muscles. However, macrophage 
population abundance was not associated with 
ABI, an indicator of disease severity, and we did not 
find a difference in CD11b+CD206− macrophage 
abundance between PAD and non- PAD muscle, 
contrary to findings showing greater inflammatory 
macrophage abundance in PAD muscles.48 Within 
individuals with PAD, there was an association be-
tween higher CD206− macrophage abundance and 
reduced walking performance, suggesting that they 
are inflammatory. However, we have not definitively 
identified this population as M1- like as we have been 
unable to successfully detect other M1 cell surface 
markers, such as CD80 and CD86, immunohisto-
chemically in human skeletal muscle. In addition, the 
small mass of frozen muscle tissue available for anal-
ysis does not permit isolation and characterization of 
macrophage functional properties.
In this same cohort of patients with PAD, we pre-
viously reported a positive correlation between fiber 
size and walking performance, measured with both 
the normal and fast  paced 4- meter walk tests.69 We 
show here that total ECM, as well as collagen con-
tent, is higher in gastrocnemius muscles from pa-
tients with PAD compared with those without PAD. 
Thus, in addition to the association of smaller over-
all calf muscle size with poor walking performance 
in PAD,92 a greater area of PAD muscle is occupied 
by noncontractile ECM/collagen compared with 
muscle in people without PAD. Additionally, we re-
port a positive association between muscle ECM 
content and capillary density with PAD. M2 macro-
phages are a source of transforming growth factor 
β, a cytokine that promotes ECM production and, if 
left unchecked, leads to fibrosis26–28; however, nei-
ther ECM nor capillary density in PAD correlated to 
CD206+ macrophage number or relative abundance. 
SR analysis of PAD muscles revealed some samples 
with excess collagen in and around capillaries, which 
may impair function so that higher capillary density 
in PAD may not necessarily improve tissue oxygen-
ation.69,93 Capillary density in muscle from patients 
with PAD is controversial, with some studies report-
ing higher capillary density with PAD69,94–96 and oth-
ers reporting lower capillary density with PAD.93,97–99 
We found a higher capillary density in PAD muscle 
compared with non- PAD muscle,69 which may rep-
resent a compensatory mechanism in patients with 
PAD who have reduced oxygen delivery, but higher 
capillary density is associated with elevated ECM 
and collagen. These findings are consistent with 
previous reports of greater collagen density in PAD 
gastrocnemius samples, particularly surrounding mi-
crovessels, and thickening of the capillary basement 
membrane with PAD.93,94,100 Further, it has been 
shown in PAD that smooth muscle cells within the 
vascular wall promote collagen deposition within 
skeletal muscles.100,101 Taken together, these find-
ings support the hypothesis that in addition to lim-
iting muscle contractile function, increased collagen 
deposition may limit capillary function, potentially 
serving as an additional stimulus for compensatory 
capillary proliferation.
Although the walking performance of patients with 
PAD is associated with ABI,3,5,71 the fact that muscle 
properties are correlated with walking performance 
independent of ABI suggests that reduced blood 
flow is not the only determinant of walking perfor-
mance in patients with PAD. To our knowledge, no 
prior studies have assessed the associations of calf 
muscle macrophages with walking performance in 
people with PAD. The uncoupling of hemodynamics 
and skeletal muscle cellular properties could reveal 
beneficial muscle adaptations to repeated ischemia- 
reperfusion that may be promoted with exercise, 
which is effective for improving walking performance 
but does not effectively increase lower extrem-
ity blood flow in patients with PAD.12–15 Restoring 
blood flow in conjunction with promoting adaptive 
muscle responses may provide the most effective ap-
proach to improve walking performance in patients 
with PAD.
Study Limitations
There are several limitations to the present study. 
First, the study is cross- sectional so no causal in-
ferences can be made. Second, the relatively small 
sample size limits the extrapolation of our findings to 
the larger population of patients with PAD. Third, be-
cause of the small sample size statistical power is low 
and future study with a larger population is needed. 
Analysis of a greater number of patients with PAD and 
a larger number of healthy gastrocnemius muscle 
samples for comparison are needed to confirm the 
associations observed. Fourth, there was a higher 
proportion of blacks in the PAD group compared with 
the non- PAD group, and statistical adjustment can-
not completely overcome this confounding. Further 
study is needed to determine the influence of race on 
muscle characteristics in patients with and patients 
without PAD. Fifth, differences between patients with 
PAD and patients without PAD may be influenced by 
other confounding variables, since the prevalence of 
diabetes mellitus, smoking, and other characteristics 
were substantially higher in participants with PAD 
compared with those without PAD. However, the small 
sample size does not allow adequate adjustment for 
potential confounders and thus is a limitation of the 
study. Finally, isolation and single- cell analyses of 
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resident muscle macrophage populations in PAD are 
required to characterize macrophage phenotypes. 
Although CD206 expression likely distinguishes in-
flammatory and anti- inflammatory macrophages, the 
function of macrophage subtypes could not be deter-
mined with these analyses.
CONCLUSIONS
Gastrocnemius muscles from people with PAD have 
a higher relative abundance of CD11b+CD206+ 
macrophages and higher ECM accumulation com-
pared with people without PAD. Among people 
with PAD, a higher relative abundance of CD206+ 
macrophages is associated with a greater number 
of satellite cells and larger muscle fiber size. Higher 
numbers of CD11b+CD206− macrophages, con-
sistent with greater inflammation, are associated 
with poorer walking performance, suggesting that 
possessing a greater proportion of CD206+ mac-
rophages in lower extremity muscle may contrib-
ute to functional preservation with PAD. Given that 
studies in animal models of hind limb ischemia show 
beneficial outcomes in muscle directly related to M2 
macrophage abundance,50,102–106 our results sug-
gest that CD206+ macrophage- mediated reparative 
processes may be ongoing in gastrocnemius mus-
cles of people with PAD and that these processes 
could be targeted to preserve walking performance.
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 Table S1. Major Resources.
Antibody/reagent Vendor or Source Catalog # Working 
concentration 
Lot # 
CD11b Cell Sciences MON1019 1 µg/mL 491019X 
CD163 Hycult Biotech HM2157 5 µg/mL 24926M0818-A 
CD206 R&D Systems AF2534 1 µg/mL VKG0112021R 
CD16B/FCGR3B LifeSpan 
BioSciences 
C409441-
50 
1:50 163838 
4’,6-diamidino-2-
phenylindole 
(DAPI) 
Thermo Fisher 
Scientific 
D1306 0.5 µg/mL 
Pax7 Developmental 
Studies 
Hybridoma Bank 
PAX7-c 3 µg/mL 
Laminin Millipore Sigma L9393 6.5 µg/mL 103M4779 
Wheat-germ 
agglutinin 
Thermo Fisher 
Scientific 
W21405 20 µg/mL 
Lectin Sigma-Aldrich L4889 20 µg/mL 063M4010V 
Biotinylated goat 
anti-mouse IgG1 
Jackson 
ImmunoResearch 
115-065-
205
1.2 µg/mL 131562 
Biotinylated rabbit 
anti-goat IgG 
Vector 
Laboratories 
BA-5000 3 µg/mL 
Streptavidin-horse 
radish peroxidase 
Thermo Fisher 
Scientific 
S911 5 µg/mL 1880067 
Streptavidin 
AlexaFluor594 
Thermo Fisher 
Scientific 
S32356 10 µg/mL 1902487 
Superboost TSA 
AlexaFluor488 
Thermo Fisher 
Scientific 
B40953 Per 
manufacturer’s 
instruction 
1910748 
Anti-Rabbit 
AlexaFluor568 
Thermo Fisher 
Scientific 
A-11036 10 µg/mL 2045347 
Anti-Rabbit 
AlexaFluor488 
Thermo Fisher 
Scientific 
A-11008 10 µg/mL 2110498 
Ulex europaeus 
(UAE1), 
biotinylated 
Vector 
Laboratories 
B-1065 20 µg/mL ZF-0904 
Gfriffonia 
Simplicifolia 
(GSL1, BSL1), 
biotinylated 
Vector 
Laboratories 
B-1105 20 µg/mL ZF-0717 
pan-Collagen Thermo Fisher 
Scientific 
PA1-85324 20 µg/mL UG2813859 
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Table S2. Relationship between muscle features and ABI in PAD patients. 
ABI 
r (95% CI) p-value
Total macrophages 
(per fiber)  
-0.071
(-0.460, 0.344) 
0.745 
CD11b+CD206- 
(per fiber)  
-0.159
(-0.526, 0.264) 
0.463 
CD11b+CD206+ 
(per fiber)
-0.037
(-0.433, 0.373) 
0.866 
CD11b+CD206+ 
(% of total 
macrophages)  
0.031 
(-0.378, 0.428) 
0.888 
Satellite cells  
(per 100 fibers) 
-0.132
(-0.506, 0.289) 
0.543 
Mean fiber size (µm) -0.118
(-0.496, 0.302) 
0.586 
ECM (% Total Area) † 0.175 
(-0.259, 0.545) 
0.429 
SR (% Total Area) † 0.049 
(-0.372, 0.451) 
0.827 
Capillary density (per 
fiber) †‡ 
-0.169
(-0.540, 0.265) 
0.446 
ABI measures are only from the leg with the lower ABI, which is the leg used to obtain 
muscle biopsies. P-value adjusted for race, *statistically significant p<0.05. r = Pearson’s 
partial correlation coefficient; n=25 PAD unless noted. 
† Based on n=24 PAD 
‡ Mean values previously reported. 
Note: Confidence intervals for the correlation coefficients are from Fisher’s z transformation. 
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Table S2. Correlations among muscle features identified on gastrocnemius cross-sections from PAD patients. 
Total macrophages 
(per fiber) 
CD206- (per fiber) CD206+ (per fiber) CD206+ 
(% of Total) 
Satellite Cells (per 
100 fibers) 
Mean fiber size 
(µm) 
Capillary density 
(lectin+/fiber) †
r 
95% CI 
p-value r 
95% CI 
p-value r 
95% CI 
p-value r 
95% CI 
p-value r 
95% CI 
p-value r 
95% CI 
p-value r 
95% CI 
p-value
Total 
macrophages 
(per fiber) 
0.841 
(0.652, 
0.927) 
<0.001* 0.984 
(0.961, 
0.993) 
<0.001* 0.213 
(-0.213, 
0.564) 
0.322 0.405 
(0.011, 
0.690) 
0.049* 0.292 
(-0.133, 
0.618) 
0.169 0.010 
(-0.404, 
0.420) 
0.965 
CD206- 
(per fiber) 
0.841 
(0.652, 
0.927) 
<0.001* 0.730 
(0.451, 
0.872) 
<0.001* -0.281
(-0.611,
0.144)
0.186 0.152 
(-0.271, 
0.521) 
0.484 0.121 
(-0.299, 
0.498) 
0.578 -0.044
(-0.447,
0.376)
0.844 
CD206+ 
(per fiber) 
0.984 
(0.961, 
0.993) 
<0.001* 0.730 
(0.451, 
0.872) 
<0.001* 0.362 
(-0.056, 
0.664) 
0.082 0.461 
(0.060, 
0.724) 
0.022* 0.328 
(-0.094, 
0.642) 
0.118 0.027 
(-0.390, 
0.434) 
0.905 
CD206+ 
(% of Total) 
0.213 
(-0.213, 
0.564) 
0.322 -0.281
(-0.611,
0.144)
0.186 0.362 
(-0.056, 
0.664) 
0.082 0.416 
(0.006, 
0.697) 
0.042* 0.397 
(-0.016, 
0.685) 
0.054 0.179 
(-0.255, 
0.548) 
0.417 
Satellite cells 
(per 100 fibers) 
0.405 
(0.011, 
0.690) 
0.049* 0.152 
(-0.271, 
0.521) 
0.484 0.461 
(0.060, 
0.724) 
0.022* 0.416 
(0.006, 
0.697) 
0.042* 0.557 
(0.186, 
0.779) 
0.004* -0.065
(-0.464,
0.358)
0.770 
Mean fiber size 
(µm) 
0.292 
(-0.133, 
0.618) 
0.169 0.121 
(-0.299, 
0.498) 
0.578 0.328 
(-0.094, 
0.642) 
0.118 0.397 
(-0.016, 
0.685) 
0.054 0.557 
(0.186, 
0.779) 
0.004* 0.138 
(-0.294, 
0.518) 
0.535 
Capillary density 
(lectin+/fiber) †
0.010 
(-0.404, 
0.420) 
0.965 -0.044
(-0.447,
0.376)
0.844 0.027 
(-0.390, 
0.434) 
0.905 0.179 
(-0.255, 
0.548) 
0.417 -0.065
(-0.464,
0.358)
0.770 0.138 
(-0.294, 
0.518) 
0.535 
Mean fiber size was determined by minimum feret diameter. P-value adjusted for race, *statistically significant p<0.05. r = Pearson’s partial 
correlation coefficient; n=25 PAD unless noted. 
† Based on n=24 PAD 
Note: Confidence intervals for the correlation coefficients are based on Fisher’s z transformation. 
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 Representative images 
showing gastrocnemius muscle sections from three different peripheral artery disease (PAD) patients. 
Satellite cell (paired box 7 (Pax7)+, green); cluster of differentiation 206 (CD206)+ macrophage (red); 
4′,6-diamidino-2-phenylindole (DAPI)+ cell nuclei (blue). Scale bar = 50 µm. 
Figure S1. Macrophages in close proximity to satellite cells.
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A) Sirius Red histochemistry showing collagen deposition around 
capillaries (black arrows) of a highly capillarized PAD patient. Left: 200x magnification, scale bar = 200 
µm. Right two panels: 400x magnification, scale bar = 100 µm. B) Collagen immunohistochemistry 
showing collagen (green) surrounding red, lectin+ capillaries (white arrows). Blue arrows point to cross-
sectional capillaries that appear to be filled with collagen. Scale bar = 50 µm. 
Figure S2. Collagen in and around capillaries in gastrocnemius from a peripheral artery disease (PAD) patient.  
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